A common IVF add-on discussion involves three tests marketed together as "the endometrial panel" — ERA (Endometrial Receptivity Analysis), EMMA (Endometrial Microbiome Metagenomic Analysis), and ALICE (Analysis of Infectious Chronic Endometritis). All three are commercial products from the same company (Igenomix, part of Vitrolife), analyzed on the same endometrial biopsy sample. Together they can add $600–$1,800 to your IVF cycle cost.
Whether they add value to your specific case is a separate question from whether they're offered. This piece walks through what each test actually measures, what the current evidence supports for outcome improvement, and when the panel is genuinely worth pursuing.
ERA: Endometrial Receptivity Analysis
What it measures: ERA analyzes gene expression patterns in an endometrial biopsy taken during a mock or medicated cycle at the projected time of embryo transfer. The analysis compares your expression pattern to a reference of "receptive" endometrium to determine whether your window of implantation (WOI) is standard or displaced (earlier or later than typical).
The theoretical benefit: if your WOI is displaced, the standard transfer timing may miss your receptive window. Personalized embryo transfer (pET) timed to your specific WOI could theoretically improve implantation.
The evidence:
| Claim | Evidence level |
|---|---|
| ERA reliably identifies displaced windows of implantation | Moderate |
| Personalized transfer timing based on ERA improves outcomes | Weak |
| ERA benefits recurrent implantation failure patients specifically | Moderate |
| ERA improves outcomes for first-time IVF patients | Not Supported |
The 2022 Cochrane review of ERA and multiple subsequent RCTs have generally not shown improved live birth rates from ERA-guided personalized transfer versus standard transfer in unselected IVF populations. The tool retains a role in specific contexts — particularly recurrent implantation failure — but is not established as a general-population improvement.
EMMA: Endometrial Microbiome Metagenomic Analysis
What it measures: EMMA analyzes the bacterial composition of the endometrium, specifically the proportion of Lactobacillus species (considered favorable) versus other bacteria (considered potentially unfavorable). The report identifies your microbiome as either "Lactobacillus-dominant" or altered.
The theoretical benefit: if the endometrial microbiome is altered (low Lactobacillus, elevated other bacteria), pre-treatment with probiotics or antibiotics may improve implantation.
The evidence:
| Claim | Evidence level |
|---|---|
| Endometrial microbiome differences exist between patients | Strong |
| Lactobacillus-dominant microbiomes correlate with better outcomes | Moderate |
| Modifying microbiome improves outcomes | Weak |
| Routine EMMA testing improves outcomes in unselected patients | Weak |
ALICE: Chronic Endometritis Detection
What it measures: ALICE detects the presence of bacteria associated with chronic endometritis — a low-grade inflammation of the endometrium that's typically asymptomatic but has been linked to implantation failure in some studies.
The theoretical benefit: if chronic endometritis is present, antibiotic treatment before embryo transfer may improve implantation outcomes.
The evidence:
| Claim | Evidence level |
|---|---|
| Chronic endometritis exists and is often asymptomatic | Strong |
| Chronic endometritis is more common in recurrent implantation failure patients | Moderate |
| Antibiotic treatment for confirmed chronic endometritis improves subsequent outcomes | Moderate |
| Routine ALICE testing improves outcomes in unselected patients | Weak |
When the Panel Is Actually Worth It
Recurrent implantation failure (RIF)
Patients with two or more failed transfers of good-quality euploid embryos may benefit from endometrial evaluation. In this context, the panel — particularly ALICE for chronic endometritis — has some clinical rationale.
Unexplained infertility with prior IVF failure
When standard IVF hasn't worked and other causes have been ruled out, endometrial factors become a reasonable investigation area.
Recurrent pregnancy loss (RPL) with chromosomally normal losses
Endometrial receptivity and inflammatory factors may contribute to some RPL cases.
When the Panel Is Being Oversold
The endometrial panel is being marketed to first-time IVF patients as a routine add-on to "maximize chances." Current evidence does not support this framing. For patients without recurrent implantation failure history, the panel's evidence base is weak. Extra cost for a first-cycle IVF patient may not be well-justified. If your clinic recommends the full panel before your first transfer without a specific indication, ask what specific factor about your case suggests it would help.
Common patterns to watch for:
- Panel recommended for patients under 35 with no prior IVF history
- Panel bundled into "premium" packages without specific case discussion
- Claims that specific percentage improvements will result from panel use
- Recommendations to repeat the panel in subsequent cycles as standard practice
What the Test Actually Involves
The panel requires an endometrial biopsy — a same-day office procedure typically performed with a small pipette. Discomfort is moderate but brief; most patients tolerate it without significant issues. The biopsy is timed to your projected transfer window, typically in a mock cycle before your actual embryo transfer cycle.
Results take 2–3 weeks. If any of the three tests come back abnormal, treatment recommendations (adjusted transfer timing for ERA, probiotics or antibiotics for EMMA/ALICE) are typically implemented in your subsequent cycle.
Colombia-Specific Considerations
The endometrial panel is available at most larger Colombian IVF programs. Pricing varies:
The endometrial panel has legitimate uses for specific patient populations — particularly those with recurrent implantation failure or unexplained IVF failure. It is not currently established as a valuable addition for first-time IVF patients or those without specific implantation issues. Discuss specifically with your REI whether your case has an indication for the panel, or whether it's being offered as a general upgrade.
Frequently Asked Questions
Should I do ERA before my first IVF cycle?
Generally, no. Current evidence does not support routine ERA testing before a first transfer in patients without specific indication. ERA is more clearly justified after two or more failed transfers of good-quality embryos.
Does insurance cover the endometrial panel?
Rarely. Most insurance carriers classify these as experimental or investigational and don't cover them. In Colombia, they're paid out of pocket as add-ons to IVF cycles.
Do I need a separate cycle for the panel?
The endometrial biopsy is typically done during a mock cycle (or a separate medicated cycle) before your actual transfer. This adds time and medication cost to your IVF timeline.
What if EMMA shows my microbiome isn't Lactobacillus-dominant?
Typical treatment is oral or vaginal probiotics for a period before retesting. Evidence that this improves outcomes is not strong, but treatment is low-risk and inexpensive.
What if ALICE shows chronic endometritis?
Standard treatment is oral antibiotics (typically doxycycline for 14 days) before transfer. Follow-up biopsy may confirm resolution before proceeding. There's better evidence for benefit in this specific scenario than for the panel's other components.
Ready to explore your options in Colombia?
Send us your recent AMH, FSH, or a brief summary of your case. We'll connect you with English-speaking REIs who can review your workup and outline realistic pathways.
Ask on WhatsApp